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Abstract
Background: There has been a recent steep growth in platelet-rich plasma (PRP) use for musculoskeletal
conditions, but findings from high quality clinical trial data are lacking in the literature. Here, we describe the
statistical analysis plan (SAP) for the Platelet-rich plasma in Achilles Tendon Healing 2 (PATH-2) trial.
Methods: PATH-2 is a pragmatic, parallel-group, multi-centre, double-blinded, randomised, placebo-controlled,
superiority trial. The study aims to evaluate the clinical efficacy of PRP in acute Achilles tendon rupture in terms of
muscle-tendon function. Patients are identified in the orthopaedic/trauma outpatient clinic. The primary outcome is
muscle-tendon work capacity from the Heel Rise Endurance Test result, expressed as the Limb Symmetry Index
(work, in joules), at 24 weeks post randomisation. Multivariate linear regression adjusting for the stratification factors
(centre and age) and additional prognostic factors will be used to investigate the adjusted effect of the
intervention. The analysis will be by modified intention-to-treat. Sensitivity analysis will assess the internal validity of
the trial results by performing a per-protocol analysis. Safety will be summarised by treatment arm for all patients
who started treatment. Secondary patient-reported outcome measures will be analysed using linear mixed effects
models to allow all data collected at all follow-up points to be considered. Missing data will be summarised and
reported by treatment arm. Missing data imputation will be performed, if appropriate.
Discussion: The PATH-2 trial will be reported in accordance with the CONSORT statement. This SAP publication will
avoid bias arising from prior knowledge of the study results. Any changes or deviations from the current SAP will
be described and justified in the final report.
Trial registration: ISRCTN registry: ISRCTN54992179, assigned 12 January 2015. ClinicalTrials.gov: NCT02302664,
received 18 November 2014. UK Clinical Research Network Study Portfolio Database: ID 17850.
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Background
Despite the lack of high quality clinical trial data, there
has been a recent steep growth in platelet-rich plasma
(PRP) use for musculoskeletal conditions given it is of
relatively low cost and minimally invasive. In 2015, the
European PRP market was valued at over US$ 35 mil-
lion, and is projected to grow at a Compound Annual
Growth Rate of more than 6% between 2016 and 2024
[1]. There is also empirical evidence that PRP injections
are being introduced in National Health Service (NHS)
clinical practice, as evidenced by the increasing appear-
ance in the media, for its potential application in the
treatment of traumatic musculoskeletal injury.
Without evidence of efficacy, the consequences of this
increased use range from the NHS incurring extra costs
for a treatment with unproven clinical effects to the
non-deployment of an effective autologous intervention.
A recent meta-analysis of PRP for orthopaedic condi-
tions stated the need for adequately powered studies to
investigate the effect of PRP using disease-specific and
patient-important outcomes [2]. There is therefore a
pressing need to undertake an adequately powered and
robustly designed study before the use of PRP becomes
widely adopted.
Here, we describe the details of the statistical analysis
plan for the Platelet-rich plasma in Achilles Tendon
Healing 2 (PATH-2) trial [3].
Methods
Study design
PATH-2 is a pragmatic, parallel-group, multi-centre,
double-blinded, randomised, placebo-controlled super-
iority trial. The study aims to evaluate the clinical effi-
cacy of PRP in acute Achilles tendon rupture
(ATR) recovery in terms of muscle-tendon function.
The PATH-2 study is taking place in 18 NHS hospitals
across the UK. Patients are identified in the ortho-
paedic/trauma outpatient clinic, usually following an
emergency hospital attendance for an ATR. Two
sub-studies are embedded within the main study to in-
vestigate the mechanism of PRP in tendon healing.
Additional details on the PATH-2 study design can be
found elsewhere [3].
Trial objectives and endpoints
The primary outcome is muscle-tendon function, as esti-
mated by the limb symmetry index (LSI), a measure ob-
tained with the Heel Rise Endurance Test (HRET),
which is a validated objective assessment of calf-muscle
work capacity [4]. The HRET involves the participant
standing on one leg, and raising and lowering the heel
repeatedly until fatigued. The uninjured leg is tested
first. Data from the movements are obtained using a
computer-controlled linear encoder. The linear encoder
measures the height of each heel rise executed and this
information is used in conjunction with the participant’s
body weight to calculate the work performed during the
test. The work during the HRET is measured for each
lower limb in joules (J). The performance of each limb is
then used to generate the LSI according to the following
formula:
LSI ¼ Injured limb measurement
Uninjured limb measurement
 100
The time window for performing the HRET data is
24 weeks (− 2 or + 8 weeks to allow some flexibility). A
summary of the study objectives and endpoints (includ-
ing the secondary outcomes) is presented in Table 1.
Eligibility criteria
Inclusion and exclusion criteria for the PATH-2 trial are
presented in Table 2.
Intervention groups
Participants are randomly assigned (1:1) to one of two
groups by the Oxford Clinical Trials Research Unit
(OCTRU) online randomisation service:
 Treatment: local anaesthetic injection to skin,
followed by PRP injection to the tendon rupture gap;
 Control: local anaesthetic injection to skin, followed
by needle insertion into tendon rupture gap.
Sample size
A total number of 214 patients (107 per arm) will provide
90% power to detect a standardised difference of 0.5 in the
LSI measured at 24 weeks post treatment, with 5% (two--
sided) significance and allowing 20% losses to follow-up.
This is based on data from the non-surgical arm of a previ-
ous study [4], where a clinically important difference of
10% with a standard deviation (SD) of 20 was observed.
This sample size will also provide 90% power and 5% (two-
sided) significance to detect a standardised effect size of 0.5
in the Achilles Tendon Rupture Score (ATRS; patient re-
ported outcome) between the two intervention groups,
based on a difference of 11 and an SD of 21.4.
However, this sample calculation was inflated as a re-
sult of a pre-specified blinded check of the assumptions
for the primary outcome variability, which took place
approximately halfway through recruitment using the
overall population data (total sample, rather than inter-
vention groups separately), as recommended by the Data
and Safety Monitoring Committee (DSMC). As of June
2017, approximately half of the patients had reached
their primary end-point and recruitment was still on-
going. Using cleaned and validated data from 75 pa-
tients, the observed SD was 24. Based on this observed
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SD of 24 (being aware that this could go up or down
with the addition of further patient data), the sample size
was recalculated.
Therefore, based on a minimum of 80% power, and
allowing for 20% loss to follow-up, a sample size of 226
patients would be required to identify a clinically import-
ant difference of 10% with an SD of 24. The DSMC ad-
vised us during this process, and it was decided that the
recruitment should overshoot to a minimum of 230 pa-
tients (to account for further minimal fluctuations on
sample size assumptions) as a feasible target in the
remaining timelines of the trial. This approach was sup-
ported by the Trial Steering Committee (TSC).
Recruitment
Patients are identified in the outpatient trauma/ortho-
paedic clinic. Information about the study is given to
suitable patients who are willing to participate, as well
as an invitation to further discussion with a member of
the research team so they have the opportunity to ask
questions. After gaining appropriate informed consent,
baseline data is collected prior to undergoing the injec-
tion treatment.
Initial and current randomisation scheme
After informed consent and baseline measurement
have been completed, participants are randomly
assigned to either PRP injection or imitation in-
jection via a central computer-based allocation ran-
domisation system provided by OCTRU, in a 1:1
allocation ratio, using undisclosed variable permuted
block sizes with stratification by recruiting site and
age group (< 55, ≥ 55 years).
 Until 16 April 2016, using variable blocks of
undisclosed bock size stratified by study site. At this
time, 43 patients were randomised.
 From 17 April 2016, using minimisation, stratified
using study site and age group, with a probabilistic
element of 0.8 being included to ensure balance at
the end of the study [5].
Table 1 Study objectives and endpoints
Objectives Endpoints
Primary:
• Evaluate the clinical efficacy of platelet-rich plasma (PRP) in acute
Achilles tendon rupture (ATR) recovery in terms of muscle-tendon
function
At 24 weeks post treatment:
• Limb Symmetry Index of work capacity during heel-rise endurance test
(HRET); maximum heel-rise height and repetitions during HRET will be
reported as secondary outcomes
Secondary:
• Evaluate the clinical efficacy of PRP in acute ATR in terms of
participant-reported functional recovery, pain and quality of life
During the first 2 weeks post treatment:
• Visual analogue scale pain daily diary [15]
At 4, 7, 13 and 24 weeks post treatment:
• Achilles Tendon Rupture Score [16]
• Patient-Specific Functional Scale [17, 18]
• SF-12 (acute) [19]
Exploratory (sub-studies):
• Determine the key components of PRP that contribute to its
mechanism of action
• Further understand, in an immunohistochemical sub-study, the mech-
anisms of PRP that may account for its clinical efficacy
• Identify the histological pathways that PRP may alter to exert its
effects; using these results and those from the PRP biological component
sub-study, inform future targeted manipulation of PRP properties to
maximise its efficacy in tendon healing
At baseline (sub-study 1)
• Blood sample for PRP component analysis (cell count, relevant tendon
active growth factors, concentrations and platelet activation); all PRP
group participants
• Whole blood analysis for cell count and concentrations; all participants.
At 6 weeks post treatment (sub-study 2):
• A needle biopsy of the healing Achilles tendon under ultrasound
guidance during an outpatient visit for immunohistochemistry analysis
(n = 16)
Table 2 PATH-2 inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Acute Achilles tendon rupture
• 18+ years of age
• Presenting and receiving treatment within 12 days
after injury
• Referred to non-operative treatment
• Ambulatory prior to injury without the use of
walking aids or assistance
• Willing to give informed consent and able to
comply with all study requirements
• Achilles tendon injuries at the insertion to the calcaneum or at the musculo-tendinous
junction
• Previous major tendon or ankle injury or deformity to either lower leg
• History of diabetes mellitus
• Known platelet abnormality or haematological disorder
• Current use of systemic cortisone or treated with anticoagulant
• Evidence of lower limb gangrene/ulcers or peripheral vascular disease
• History of hepatic or renal impairment or dialysis
• Pregnant or breast feeding
• Having received radiation or chemotherapy within the last 3 months
• With inadequate venous access for drawing blood
• Any other significant disease or disorder which, in the opinion of the Investigator, may
either put the participant at risk or influence study results
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The reason for changing the original randomisation
scheme was that, during a routine monitoring of the
randomisation system, it was discovered that the online
system was incorrectly taking information from the age
group field prior to it being populated. This led to the
age strata not being considered and a slight imbalance of
treatment allocations in the different age group strata.
To allow randomisation recovering from this imbal-
ance, the randomisation system was updated to include
minimisation (using site and age group entered manually
to the system).
Blinding
Participants should remain blind to allocation throughout
the study. The study staff involved in treatment delivery
are aware of treatment allocation due to the nature of the
intervention. Blinded assessors unaware of treatment allo-
cation will carry out study follow-up (including the HRET
at 24 weeks). When any hospital notes are updated relat-
ing to treatment or General Practitioner letters dictated, it
is recorded that an injection was delivered as per the ran-
dom allocation assigned by the PATH-2 study without
specifying the type of injection.
Participants are invited to participate in a secondary
24-month extended follow-up and therefore are not in-
formed of their allocation after the 24-week primary end-
point follow-up. After the extended follow-up is complete,
participants may be informed of their treatment allocation
by post, text or email if a request is made. The James et al.
[6] and Bang et al. [7] indices, designed to assess whether
participants were successfully blinded to the intervention
they received, will also be calculated and reported with re-
spective 95% confidence intervals.
Data collection, quality control and data validation
Baseline data is collected from participants and site
personnel via paper case report forms (CRFs), which are
then returned to the central trial office by post using a
Freepost address (pre-paid). In some cases, CRFs may be
collected during a site visit/face-to-face meeting with a
member of the local team. Data collection at the 4, 7
and 13 week follow-up points is done by telephone call
or during a face-to-face outpatient appointment with re-
sponses recorded directly onto the CRFs. Where neces-
sary, a member of the central research team in Oxford
carries out telephone follow-up. A postal option of data
collection may be used as necessary.
Blood and needle biopsy samples sent for analysis are
anonymised at source and only identified using the unique
study number and participant initials. Blood samples are
stored at the Centre for Translational Inflammation
Research at the Birmingham University Research Labora-
tory, and will be disposed of at the end of the study. Nee-
dle biopsy samples for those participants taking part in
sub-study 2 (n = 16) are stored in the Oxford Musculo-
skeletal Biobank. Any data provided from the blood sam-
ple analysis or biopsy samples analysis are entered into the
study database in Oxford. Data will be transferred using
appropriate password protected and/or encrypted files.
The HRET data is collected from the participant dur-
ing a face-to-face visit at 24 weeks. Movement data dur-
ing the HRET are recorded via the linear encoder linked
to a study-dedicated laptop, then transferred to the
study-dedicated database in Oxford. A study-specific
version of the MuscleLab software (Ergotest Innovation
AS, Norway) is used to run and record the HRET data.
Since the encoder is a very sensitive device, it records
even minimal movements that might not correspond to
actual heel rises. To dismiss potential measurement er-
rors, where a participant provides consent, a video is
made of the ankle/leg movements associated with the
HRET. The video file contains no identifying details;
only the unique study number is used. The file is sent to
the central coordinating team in Oxford where two
members of the study team blinded to treatment alloca-
tion independently review them, discounting any invalid
repetition included in the HRET data (e.g. minimal
movements that do not consist in actual heel rises, but
that are captured by the assessment device). To ensure
validity of data, intra-class correlation coefficients will be
calculated for the two revised measurements before con-
sensus on the number of valid heel rise repetitions is
achieved.
The central study office receives the CRFs and the coord-
inating team carries out appropriate data quality and valid-
ation checks. The data is entered into a study-dedicated
database developed and maintained by OCTRU using
OpenClinica software. To identify manual entry errors, a
10% double entry check of follow-up questionnaires is car-
ried out at regular intervals during the data collection phase
of the study. No data will be considered spurious in the
analysis since all data will be checked and cleaned before
analysis.
Specification of statistical packages
All analysis will be carried out using appropriate vali-
dated statistical software such as STATA, SAS, SPLUS
or R statistical software. The relevant package and ver-
sion number will be recorded in the Statistical report.
Interim analysis and stopping rules
There were no formal interim analyses of the outcomes
planned for PATH-2. However, the DSMC has checked
the sample size assumptions, as detailed above, and the
funder carried out an assessment of study feasibility after
the 10th month following the start of recruitment. The
feasibility criteria considered are presented in Table 3.
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These criteria were met and discussed with the inde-
pendent DSMC, and a recommendation for the continu-
ation of the study was made to the independent TSC.
The TSC confirmed the final decision and reported to
the funder. The DSMC did not request any further in-
terim analyses.
Descriptive analysis of participant flow
A summary of participants through the trial will be pre-
sented for each group. The number of participants through
each stage of the trial will be provided in a flow diagram as
suggested by CONSORT (Fig. 1). Protocol violations/de-
viations and information relating to the screening data,
including the number of ineligible patients randomised, to-
gether with reasons, will be also reported.
Baseline comparability of randomised groups
Numbers (with percentages) for binary or categorical vari-
ables and means (with standard deviations) or medians
(with lower and upper quartiles) for continuous variables
will be presented; there will be no tests of statistical
significance nor confidence intervals for differences
between randomised groups on any baseline variable.
Additional file 1: Tables S1–S8 give the complete list of
baseline variables.
Comparison of losses to follow-up
The numbers (with percentages) of losses to follow-up
(defaulters and withdrawals) over the study time points,
and for each analysis endpoint, will be reported and
compared between the PRP and imitation injection
groups. To ensure that there are no differential losses
between the groups, this will be tested using absolute
risk differences (with 95% confidence interval) and a χ2
test. Deaths and their causes will be reported separately.
Quality assurance and compliance with intervention
Intervention involves a single injection of PRP after
blood sample collection and PRP preparation, or the
introduction of a dry needle, into the tendon tissue [3].
Quality assurance will be undertaken using the times
Table 3 Trial feasibility criteria as per the funder request
Criteria Target
Number of sites open to
recruitment
7
Ratio of patients
consented/eligible
≥ 20%
Number of participants
randomised
≥ 50
Compliance with
intervention
Subjective, percentage of non-compliers to
be considered
Loss to follow-up ≤ 30%
Safety Subjective, all adverse events and serious
adverse events considered
Fig. 1 CONSORT flow diagram of participants in the trial
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recorded regarding key processes related to the interven-
tion preparation and delivery. A summary of the treat-
ment received will be provided, including information on
the timeframes for PRP preparation and analysis and
grade of the healthcare professional delivering the treat-
ment. Compliance with treatment and any protocol devia-
tions prior to or during the intervention procedure will be
reported totally and separately by treatment arms with
reasons for not receiving the assigned injection. A χ2 test
(or equivalent) will be used to examine whether compli-
ance differs significantly between intervention groups.
Blinded analysis
A blinded analysis of data (not separated by treatment
arm) will be undertaken prior to the final data lock in
order to clarify whether continuous variables are nor-
mally distributed and to finalise the identification of the
participants who will be excluded from the per-protocol
(PP) analysis. This analysis may also be used to identify
key prognostic variables to be included in the adjusted
analysis. The Statistical Analysis Plan will be updated be-
fore the final analysis of the trial, in case of any changes
at this stage. These changes will be justified in the final
Study Report.
Definition of populations for analysis
 Intention-to-treat (ITT) analysis: inclusion of all
randomised participants who will be analysed in the
groups to which they were allocated. For the
primary outcome, analysis will include a modified
ITT population defined as all randomised ITT
participants with available LSI data (i.e. at least one
valid rep for each lower limb after HRET data
validation by the blinded reviewers of the
assessment video files).
 Per-protocol (PP) analysis: participants analysed in
the group of the treatment they actually received.
Patients who had major protocol violations/
deviation will be excluded from the PP population.
Patients who receive ‘poor quality’ PRP injection
(e.g. PRP with concentrations of platelets lower than
in their whole blood) will be excluded. The
definition of PP analysis population will be finalised
during a blinded analysis of the data (not separated
by treatment) prior to the primary analysis time
point and justified in the final Study Report.
 Safety analysis: All participants who received the
intervention that they were allocated to, as defined
in the protocol.
Analyses to address the primary aim
For the primary outcome, analysis will be a performed
on a modified ITT basis as defined above, comparing
intervention (PRP injection) against control (Imitation
injection). A two-sided p value of 0.05 (5% significance
level) will be used to indicate statistical significance.
Exact p values will be presented up to three decimal
places. Multivariate linear regression, using the LSI as a
continuous dependent variable, treatment as the main
independent variable and the stratification factors
(centre and age group) as additional independent vari-
ables, will be used to investigate the adjusted effect of
PRP on ATR recovery. Supplementary analyses will re-
peat the primary analysis also adjusting for other prog-
nostic factors such as sex, body mass index, smoking
status and use of antiplatelet medication. The primary
analysis used to assess the treatment effect will be the
fully adjusted analysis based on the modified ITT popu-
lation, with the other analyses being used to ensure ro-
bustness of results.
If data on the primary outcome is not normally distrib-
uted, the first approach will be data transformation (such
as logarithm, exponential or other type of transformation).
If normality cannot be achieved by data transformation, a
non-parametric statistical test (e.g. Wilcoxon–Mann–
Whitney test for testing whether the population medians
of the two groups are the same) will be used. In this case,
no adjustment will be made.
Missing data
There are two main categories of missing data for the
HRET assessment, namely (1) missing data for specific
repetitions of heel rise (values of displacement missing
or recorded as zero by the software) and (2) missing data
for entire assessments (for one or both legs; derived
from missing appointments, refusal or inability to per-
form the test appropriately, and missing data files). The
first approach to handling missing data will be to impute
the average (mean or median values, depending on the
data distribution; checked for the total population dur-
ing the blinded analysis) concentric displacement (up-
wards movement) for missing measurements due to the
unlikely event of technical device failure during the con-
duct of an assessment (first group of missing data). Mul-
tiple imputation by chained equations [8] may be used
to estimate the LSI for those patients with entire files
compromised or unavailable for any reason (second
group of missing data) and for the prognostic variables,
in case of substantial amount of missing data (e.g. > 20%
for a single variable). If multiple imputation is used, then
this will be regarded as a sensitivity analysis to assess the
robustness of the results. In this case, multiple imput-
ation by chained equations will comprise the same vari-
ables included in the fully adjusted model used to
investigate the effect of the intervention on the primary
outcome (i.e. the stratification and other prognostic fac-
tors such as sex, body mass index, smoking status and
Schlüssel et al. Trials  (2018) 19:464 Page 6 of 10
use of antiplatelet medication), plus an indicator of treat-
ment group and the outcome. This process creates a
series of complete datasets (observed + imputed data) in
which the analyses described in this document will be
performed individually. The regression parameter esti-
mates plus corresponding standard errors obtained from
the analyses of each imputed dataset will then be com-
bined using Rubin’s Rules [9]. Where missing data im-
putation is used, imputed values will also be verified
using the validation checks described above to ensure
the missing values have been imputed within the limits
of the data.
Pre-specified subgroup analysis
No formal subgroup comparative analysis is planned.
However, treatment effects within subgroups, assessed
using interaction between treatment and the subgroup,
will be presented using forest plots to visually examine
whether the effect of PRP injection compared to imita-
tion differs based on the stratification factors (age group
and centre) and other prognostic variables such as sex,
body mass index categories, smoking status, PRP quality
(assessed in terms of platelet concentration and activa-
tion) and pain levels during the first 2 weeks after treat-
ment (as measured by the visual analogue scale diaries).
Sensitivity analysis
A sensitivity analysis will be performed on a PP basis to
examine robustness of conclusions and to assess different
assumptions about departures from randomised policies.
The PP population is as defined above and will be finalised
during the blinded analysis. Sensitivity analysis excluding
potential outliers or extremely unexpected observations
(e.g. patients with a value of LSI much higher than 100%,
meaning that the injured leg performed much better than
the uninjured one in the HRET) will be conducted to
check the robustness of the main findings.
Analysis to address secondary aims
The primary analysis for all secondary outcomes will be
performed on an ITT basis, comparing intervention
(PRP injection) against control (Imitation injection). For
the analyses of the secondary outcomes a p value of 0.05
(5% significance level) will be used to indicate statistical
significance and treatment effects reported with 95%
confidence intervals. Exact p values will be presented up
to three decimal places.
Linear mixed effects regression models will be used to
allow the data collected at all follow-up time-points to
be considered and adjusting for pre-injury and baseline
scores where applicable. This is a robust procedure cap-
able of dealing with some missing values, either due to
missed visits or to a patient leaving the study prema-
turely. Time elapsed from the intervention to the
outcome measurement will be included in the models as
a random effect factor, considering that not all patients
will have their follow-up assessments at exactly the same
time. These analyses will be adjusted for the stratifica-
tion factors and, if applicable, for the same prognostic
factors included in the adjusted analysis of the primary
outcome. Mean differences and 95% confidence intervals
will also be reported. If normality is not observed for
any of the continuous secondary outcomes, the first ap-
proach will be data transformation. If normality cannot
be achieved by data transformation, the same strategy
adopted for the primary outcome will be used.
Self-reported pain in the first 2 weeks after randomisa-
tion will also be represented graphically using informa-
tion obtained from the pain diary. Supplementary
analyses will include using area under the curve sum-
mary statistics calculated from parameters estimated
with linear mixed models, to provide an overall estimate
of recovery over time [10]. Pain for each treatment
group will also be explored using the pain section of the
ATRS score collected at 4, 7, 13 and 24 weeks.
Pre-specified subgroups and sensitivity analyses for
secondary outcomes
No formal subgroup comparative analyses will be under-
taken for secondary outcomes. However, results for key
secondary outcome (ATRS) will be presented using for-
est plots as described above for the primary outcome. In
the particular case of the ATRS, the study sample pro-
vides 90% power to detect a difference of 11 points with
an SD of 21.4 (standardised effect size of 0.5) at 5%
(two-sided) significance level. Sensitivity analysis will be
performed on a PP basis to examine robustness of con-
clusions based on the results observed for the ATRS.
This will be to investigate different assumptions about
departures from randomised policies, as well as to check
the validity of multiple imputation assumptions where
applicable.
Supplementary analysis: 24-month participant reported
data
Patient-Specific Functional Scale, visual analogue scale
and ATRS data will be collected at 24 months after in-
jury by post or telephone call to permit an exploratory
analysis of any effects of PRP beyond 24 weeks. A differ-
ence in speed of healing, if evident, will be seen when
the tendon is in the recovery phase; the primary out-
come measure at 6 months after injury is timed to cap-
ture this data. However, restoring the final level of
function, sport and work occurs over a longer period fol-
lowing ATR, with an overall recovery time of 2 or more
years post injury [1]. If PRP affects the quality of the
repaired tendon, we would expect to see this at 2 years
post injury. Academic/employment status and physical
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activity-related data will also be collected at 24 months
and exploratory analysis will be performed. These sup-
plementary analyses will be published separately from
the main study results.
Health economics and cost effectiveness
No health economics or cost-effectiveness analysis is
planned for PATH-2.
Harms
To the best of our knowledge there have been no serious
adverse events (SAEs) related to using PRP reported in the
literature. Unforeseeable events related to the study treat-
ments will be reported as an SAE if they take place within
24 weeks of receiving trial treatment/imitation and fulfil the
SAE criteria. Other adverse events related to the trial inter-
ventions and condition may be reported by site staff or by
patients. Following completion of follow-up, duplicate ad-
verse event reports will be identified, such that each adverse
event is recorded no more than once for each patient. The
number (and percentage) of patients experiencing each type
of event will be presented for each treatment arm, cate-
gorised as per the protocol (Table 4). The safety analysis for
PATH-2 will be performed on the Safety population as de-
fined above. SAEs will be monitored at each follow-up
point. A comparison of SAEs between the PRP and imita-
tion injection groups will be assessed by examination of
95% confidence intervals for the difference in incidence. An
overall category for any SAE will also be compared.
Additional exploratory analysis not specified prior to
receiving data
Any analyses not specified in this Statistical Analysis
Plan will be exploratory in nature and a significance
level of 0.01 will be used to declare statistical signifi-
cance; 99% confidence intervals will be presented.
Patient and public involvement
The PATH-2 TSC includes a patient and public in-
volvement representative who advises on patients’ pri-
orities, experiences and preferences. This includes,
but is not restricted to, recruitment strategies, burden
of intervention, relevance of outcomes and dissemin-
ation of results.
Ethics and dissemination
The trial will be reported in accordance with the CON-
SORT statement [11] and its extensions relating to
non-pharmacological studies [12, 13] and TIDieR (template
for intervention description and replication) guidelines for
intervention description and replication [14]. Further details
on the ethical aspects of the trial and dissemination plan
can be found in the protocol publication [3].
Discussion
This manuscript was written based on the PATH-2 Proto-
col version 6.0 and SAP version 2.0. This Statistical Ana-
lysis Plan publication will avoid bias arising from prior
knowledge of the study results. Any changes or deviations
from the current Statistical Analysis Plan will be described
and justified in the final report.
Update on recruitment closure and follow-up
The PATH-2 trial recruited participants between July
2015 and September 2017. Follow-up for the primary
analysis will be completed by March 2018 and the trial
is due to report results in August 2018.
Additional file
Additional file 1: Table S1. Baseline characteristics of participants
according to intervention groups. Table S2. Stratification factors and
sociodemographic characteristics of participants according to
intervention groups. Table S3. Baseline patient reported outcomes
by intervention groups. Table S4. Academic/employment-related
characteristics of participants according to intervention groups. Table
S5. Physical activity of participants before injury according to
intervention groups. Table S6. Injury-related characteristics of partici-
pants by intervention groups. Table S7. Clinical characteristics of par-
ticipants by intervention groups. Table S8. Medications that may
influence platelet function taken by participants by intervention
groups. Table S9. Complications reported by participants during the
24 weeks after injury and treatment. (PDF 1944 kb)
Table 4 Serious adverse events and adverse events
Serious adverse events
An untoward medical occurrence that:
• Results in death
• Is life-threatening
• Requires in-patient hospitalisation or prolongation of existing
hospitalisation
• Results in persistent or significant disability/incapacity
• Leads to a congenital anomaly/birth defect
• Other important medical events
Adverse events (related to study treatment or condition that do not
require specific time-critical reporting but may be collected as part of
standard data collection in the PATH-2 trial)
Foreseeable adverse events
• Bruising and discomfort at the venesection site
• Mild discomfort or minor bleeding from ATR site following injection
• Technical complications of the lower leg casting and splinting
• Consequences of depending on walking aids
• Syncopal (fainting) episode associated with venesection or tendon
injection
• Discomfort at ATR site during rehabilitation
• Swelling or bruising of the lower leg and foot
• Deep vein thrombosis in a lower limb
• Re-rupture of the treated Achilles tendon (including any surgery on
the Achilles tendon treated in the study)
Unforeseeable adverse events
• Serious infection of ATR injection site
• Skin breakdown or ulceration of treated lower leg other than ‘plaster
sores’
• Severe pain requiring more than simple analgesia beyond 10 days
after injection
Other adverse events not pre-specified but deemed related to treatment
or condition will also be recorded and reported
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